Drug updated on 6/25/2024
Dosage Form | Injection (intravenous; 500 mg/10 mL [50 mg/mL], 120 mg/2.4 mL [50 mg/mL]) |
Drug Class | Programmed death-ligand 1 blocking antibodies |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with unresectable, Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
- Indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
- Indicated in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
- Indicated in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC).
- Indicated in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).
- Indicated in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Durvalumab (Imfinzi) is indicated for the treatment of adult patients with various types of lung cancer and biliary tract cancer, as well as unresectable hepatocellular carcinoma. It can be used alone or in combination with other drugs such as etoposide, carboplatin, cisplatin, tremelimumab-actl, and gemcitabine.
- A total of 20 studies were reviewed to gather information about durvalumab's effectiveness and safety compared to other therapeutic options like nivolumab, pembrolizumab, atezolizumab, and immune checkpoint inhibitors combined with chemotherapies.
- In terms of hepatocellular carcinoma (HCC) with PVTT treatment outcomes, HAIC-FO combined with sorafenib showed more favorable results than combinations involving durvalumab.
- For Stage III Unresectable NSCLC patients who have undergone concurrent platinum-based chemotherapy and radiation therapy without disease progression, post-treatment use of durvalumab is associated with significant improvement in 1-year overall survival rates (OS) and progression-free survival rates (PFS).
- When treating extensive-stage small cell lung cancer (ES-SCLC), although effective when used alongside chemotherapy, durvalumab was found less beneficial than serplulimab regarding OS & PFS benefits, positioning it as a viable but not the most effective option within this indication.
- Durvalumab has shown promising potential when paired with gemcitabine for advanced BTC treatments by offering a balance between tolerability and enhanced survival outcomes.
- In real-world scenarios involving the stage III NSCLC patient population, durvalumab demonstrated similar safety and efficacy profiles to those observed during clinical trials, despite the inclusion of a broader patient population, thus highlighting its practical applicability.
- The incidence of adverse events across indications, especially among elderly patients or those with compromised performance status, emphasizes the importance of monitoring and managing potential toxicities while using the drug.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Imfinzi (durvalumab) Prescribing Information. | 2023 | AstraZeneca Pharmaceuticals LP., Wilmington, DE |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
A practical guide for the systemic treatment of biliary tract cancer in Canada. | 2023 | Current Oncology |
Society for immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. | 2022 | Journal for Immunotherapy of Cancer |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. | 2020 | Annals of Oncology |
Management of immunotherapy-related toxicities, version 1.2019, NCCN Clinical Practice Guidelines in Oncology. | 2019 | Journal of the National Comprehensive Cancer Network |